A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence

被引：0
|
作者：
Dignass, A. [1 ]
Gisbert, J. P. [2 ]
Bossa, F. [3 ]
Kelly, O. [4 ]
Rahman, M. [5 ]
Lobaton, T. [6 ]
Addison, J. [7 ]
机构：
[1] Goethe Univ, Agaples Markus Hosp, Dept Med 1, Frankfurt, Germany
[2] Univ Autonoma Madrid UAM, Hosp Univ La Princesa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria Princesa IIS Princesa,Gastr, Madrid, Spain
[3] Fdn Casa Sollievo Sofferenza, Div Gastroenterol, IRCCS San Giovanni Rotondo, Puglia, Italy
[4] Connolly Hosp, Dept Gastroenterol, Dublin, Ireland
[5] Surrey & Sussex Healthcare NHS Trust, Dept Gastroenterol, Surrey, England
[6] Ghent Univ Hosp, Dept Internal Med & Pediat, Dept Gastroenterol, Ghent, Belgium
[7] Biogen Idec Ltd, Clin Res, Maidenhead, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P431
引用
收藏
页码：558 / 559
页数：2
相关论文
共 46 条
  • [1] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
    Ulf Müller-Ladner
    Axel Dignass
    Karl Gaffney
    Deepak Jadon
    Marco Matucci-Cerinic
    Triana Lobaton
    Philippe Carron
    Javier P. Gisbert
    Ira Pande
    Maximilian Utzinger
    Janet Addison
    BioDrugs, 2023, 37 : 873 - 889
  • [2] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease
    Mueller-Ladner, Ulf
    Dignass, Axel
    Gaffney, Karl
    Jadon, Deepak
    Matucci-Cerinic, Marco
    Lobaton, Triana
    Carron, Philippe
    Gisbert, Javier P.
    Pande, Ira
    Utzinger, Maximilian
    Addison, Janet
    BIODRUGS, 2023, 37 (06) : 873 - 889
  • [3] The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease
    Dignass, A. U.
    Gisbert, J. P.
    Bossa, F.
    Freudensprung, U.
    Addison, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I418 - I418
  • [4] The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease
    Dignass, A. U.
    Gisbert, J. P.
    Bossa, F.
    Freudensprung, U.
    Addison, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I418 - I418
  • [5] The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease
    Dignass, A.
    Gisbert, J.
    Freudensprung, U.
    Addison, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S459 - S460
  • [6] THE PROPER STUDY: A 48-WEEK ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS
    Mueller-Ladner, U.
    Gaffney, K.
    Jadon, D.
    Matucci-Cerinic, M.
    Chamizo Carmona, E.
    Freudensprung, U.
    Addison, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1299 - 1300
  • [7] A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
    Mueller-Ladner, Ulf
    Gaffney, Karl
    Jadon, Deepak
    Matucci-Cerinic, Marco
    Chamizo Carmona, Eugenio
    Addison, Janet
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2826 - 2828
  • [8] The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
    Mueller-Ladner, Ulf
    Gaffney, Karl
    Jadon, Deepak
    Freudensprung, Ulrich
    Addison, Janet
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1689 - 1691
  • [9] THE PROPER STUDY: INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS
    Mueller-Ladner, U.
    Gaffney, K.
    Jadon, D.
    Freudensprung, U.
    Addison, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1126 - 1127
  • [10] THE PROPER STUDY: RESULTS OF THE FIRST INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS
    Mueller-Ladner, U.
    Gaffney, K.
    Jadon, D.
    Freudensprung, U.
    Addison, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1450 - 1451
12345